Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Enzyme-Linked Immunosorbent Assay

Enzyme-Linked Immunosorbent Assay

In 1971, Peter Perlman and Eva Engvall developed an Enzyme-linked immunosorbent assay (ELISA or EIA). ELISA differs from western blot in that the assays are conducted in microtiter plates or in vivo rather than on an absorbent membrane.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen. Enzyme-substrate reaction allows the antigen to be visualized or quantified.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Safety and immunogenicity of mRNA-based mpox vaccine candidate BNT166a: an open-label, dose-escalation, first-in-human trial.

The Lancet. Infectious diseases·2026

Same author

A Study to Investigate the Safety and Immunogenicity of Monovalent Omicron LP.8.1-Adapted BNT162b2 COVID-19 Vaccine in Adults ≥ 65 Years of Age and High-Risk Adults 18-64 Years of Age (Preliminary Results).

Vaccines·2026

Same author

Application of Allometric Scaling and Translational Modeling to Predict Human Pharmacokinetics of mRNA-Encoded Antibodies.

Molecular pharmaceutics·2026

Same author

Strong and early immune responses against SARS-CoV-2 in mice and rhesus macaques after BNT162b3 vaccination.

NPJ vaccines·2026

Same author

T-cell Response Induced by the BNT162b2 COVID-19 Vaccine in Children.

Open forum infectious diseases·2025

Same author

Claudin 6 is a suitable target for CAR T-cell therapy in atypical teratoid/rhabdoid brain tumors and other pediatric solid tumors.

Journal for immunotherapy of cancer·2025

Search research articles

Related Experiment Video

Updated: May 8, 2026

Developing a Salivary Antibody Multiplex Immunoassay to Measure Human Exposure to Environmental Pathogens

Developing a Salivary Antibody Multiplex Immunoassay to Measure Human Exposure to Environmental Pathogens

Published on: September 12, 2016

Antigen identification using SEREX.

Ugur Sahin¹, Ozlem Türeci

¹Translational Oncology (TRON), Mainz, Germany.

Methods in Molecular Biology (Clifton, N.J.)

|August 22, 2013

Summary

This summary is machine-generated.

Serological analysis of recombinant cDNA expression libraries (SEREX) identifies cancer and autoimmune disease autoantigens. This method screens diseased tissue libraries with patient serum for autoantibody targets.

More Related Videos

Simultaneous Detection of Different Antibody Classes in a Multiplexed Serological Test

Simultaneous Detection of Different Antibody Classes in a Multiplexed Serological Test

Published on: July 14, 2023

Related Experiment Videos

Last Updated: May 8, 2026

Developing a Salivary Antibody Multiplex Immunoassay to Measure Human Exposure to Environmental Pathogens

Developing a Salivary Antibody Multiplex Immunoassay to Measure Human Exposure to Environmental Pathogens

Published on: September 12, 2016

Simultaneous Detection of Different Antibody Classes in a Multiplexed Serological Test

Simultaneous Detection of Different Antibody Classes in a Multiplexed Serological Test

Published on: July 14, 2023

Area of Science:

Immunology
Molecular Biology
Oncology

Background:

Autoantibodies are key biomarkers in autoimmune diseases and cancer.
Identifying autoantigens is crucial for understanding disease mechanisms and developing diagnostics/therapeutics.

Purpose of the Study:

To provide protocols for Serological analysis of recombinant cDNA expression libraries (SEREX).
To enable systematic identification of autoantigens recognized by patient autoantibodies.

Main Methods:

Construction of lambda phage expression libraries from diseased tissue.
Screening of these libraries with autologous patient serum (SEREX immunoscreening).
Downstream validation of identified autoantigens.

Main Results:

SEREX facilitates the discovery of novel autoantigens.
The identified autoantigens are recognized by spontaneous autoantibodies in patients.
Protocols are detailed for reproducible SEREX application.

Conclusions:

SEREX is a powerful tool for systematic autoantigen discovery in cancer and autoimmune diseases.
The provided protocols support the application and validation of SEREX.
This approach aids in understanding the autoantibody repertoire in disease.